Founded in 2004, Abacus Medicine is, according to its own estimates, the fastest-growing parallel trade company of original prescription pharmaceuticals in Europe.

During the period from 2016 to 2018, the company grew revenues by approximately 37% per year on average and gained significant market share across Europe.

In May 2019, the company announced an initial public offering on the Prime Standard of the Frankfurt Stock Exchange.